title: Tumstatin 185-191 increases the sensitivity of non-small cell lung carcinoma cells to cisplatin by blocking proliferation, promoting apoptosis and inhibiting Akt activation.
abstract: OBJECTIVE
  This study aimed to investigate the synergistic anti-tumor effects of tumstatin 185-191 and cisplatin in non-small cell lung carcinoma cells (NSCLC) (A549 cells and cisplatin resistant A549/DDP cells), and the potential role of Akt signaling pathway was also explored.
  
  
  METHODS
  A549 or A549/DDP cells were treated with Tum185-191 or Tum185-191 plus cisplatin. Cell viability was assessed by modified MTT assay. 50% inhibiting concentration (IC50) and reversing drug-resistance index (RI) of chemotherapeutics were determined by MTT assay. Cell apoptosis was measured by Hoechst 33258 staining and flow cytometry. The activation of Akt signaling pathway was evaluated by immunocytochemistry and Western blot assay.
  
  
  RESULTS
  Tum185-191 inhibited the proliferation of A549 cells and A549/DDP cells. In the presence of Tum185-191 (20 and 40 μM), IC50 of cisplatin reduced significantly in A549 cells and A549/DDP cells. Combined use of tumstatin 185-191 and cisplatin exerted synergistic effects in promoting apoptosis. A549 and A549/DDP cells had a high expression of p-Akt, and Tum185-191, but not cisplatin, significantly inhibited p-Akt expression. Combined use of cisplatin and Tum185-191 failed to further inhibit p-Akt expression. After Tum185-191 treatment, the increased p-Akt expression was observed at 15 min, peaked at 30-60 min, but disappeared at 120 min.
  
  
  CONCLUSIONS
  Tum185-191 increases the apoptosis, inhibit the proliferation, enhance the sensitivity of A549 cells to cisplatin and also partly reverse the resistance of A549-DDP cells to cisplatin, which is at least partially mediated by inactivating Akt pathway. These findings provide evidence for the chemotherapy of NSCLC with Tum185-191 and cisplatin.
authors.affiliation: Department of Thoracic Medicine, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University Changsha 410013, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.affiliation: Department of Respiratory Medicine, The Second Xiangya Hospital, Central South University Changsha 410011, China.
authors.forename: Ping
authors.initials: P
authors.lastname: Chen
authors.affiliation: Department of Thoracic Medicine, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University Changsha 410013, China.
authors.forename: Min
authors.initials: M
authors.lastname: Tang
authors.affiliation: Department of Respiratory Medicine, The Second Xiangya Hospital, Central South University Changsha 410011, China.
authors.forename: Junli
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Respiratory Medicine, The Second Xiangya Hospital, Central South University Changsha 410011, China.
authors.forename: Yanfang
authors.initials: Y
authors.lastname: Pei
authors.affiliation: Department of Respiratory Medicine, The Second Xiangya Hospital, Central South University Changsha 410011, China.
authors.forename: Shan
authors.initials: S
authors.lastname: Cai
authors.affiliation: Department of Oncology Plastic Surgery, Department of Head and Neck Surgery, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University Changsha 410013, China.
authors.forename: Xiao
authors.initials: X
authors.lastname: Zhou
authors.affiliation: Department of Pathology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University Changsha 410013, China.
authors.forename: Senlin
authors.initials: S
authors.lastname: Chen
keywords: Akt; Non-small cell lung carcinoma cells; Tumstain 185-191; cisplatin